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INTRODUCTION 
 Collagen vascular diseases like Systemic Lupus Erythematosus (SLE) and 
Systemic Sclerosis (SSc) are always a challenge to the treating dermatologists. Though 
complete cure remains an enigma, therapeutic advances have aimed at inducing quick 
remission and improving the quality of life of the patients. 
 Pulse therapy is administration of single or multiple daily infusions of 
suprapharmacological doses of drugs to achieve a desired therapeutic effect. It is 
otherwise called as the “big shot “.1The history of pulse therapy began in 1969 when 
Kountz and Cohn introduced methylprednislone pulse therapy to prevent renal graft 
rejection.2   
 The monumental success of Dexamethasone Cyclophosphamide pulse therapy 
(DCP) in autoimmune bullous diseases (eg.Pemphigus) reported by Pasrischa et al., has 
prompted dermatologists to use DCP in collagen vascular diseases. 3 
 Collagen vascular disorders are a group of diseases characterized by 
generalised alteration in connective tissue and have certain common features like 
autoimmunity, disordered cell mediated immunity, vascular abnormalities, arthralgia 
and skin disease.4 
 The diseases grouped under this category include lupus erythematosus, 
systemic sclerosis, localised and generalised morphoea, dermatomyositis, rheumatoid 
arthritis and Sjogren’s syndrome. 
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 Since the use of the first pulse therapy in collagen vascular disorders in 1976 
for lupus nephritis, it has come a long way in improving the quality of life of patients. 
Now it is used in dermatomyositis, systemic sclerosis, mixed connective tissue disease 
and rheumatoid arthritis. 
  The long duration of steroid therapy required and the consequent effect on 
hypothalamo-pituitary axis (HPA) suppression with daily steroids makes pulse therapy, 
which is relatively free of such effects a welcome option in the therapeutic 
armamentarium of treatment of collagen vascular diseases. 
 Although success of pulse therapy in collagen vascular disease has been 
reported in the form of case reports, until the last decade there has not been any well 
documented clinical trials.  
 Documented success of DCP in collagen vascular diseases have come from 
Indian studies by Dhabai et al., published in 2005 that used DCP in SLE and by Ahmad 
et al who reported improvement in systemic sclerosis with DCP in 2003.5,6 
 This study aims at using Dexamethasone- Cyclophosphamide pulse therapy for 
systemic lupus erythematosus and systemic sclerosis since these are the most 
common collagen vascular diseases seen in our out patient department. 
 Also the novel aspect of this study is that the clinical improvement of 
dermatological manifestations will be based on well validated skin scoring systems. 
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AIMS & OBJECTIVES: 
 To study the efficacy of Dexamethasone –Cyclophosphamide pulse therapy in 
collagen vascular disorders. 
1. To evaluate the degree of clinical and serological remission in Systemic Lupus 
Erythematosus and Systemic Sclerosis. 
2. To evaluate the duration required to induce clinical remission. 
3.  To evaluate side effects of pulse therapy. 
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REVIEW OF LITERATURE 
PULSE THERAPY- DEFINITION: 
 Pulse therapy is defined as “the administration of suprapharmacological doses 
of drugs in an intermittent manner to enhance the therapeutic effect and reduce the 
side effects.”1 
 A wide number of drugs are used as pulse therapy in a wide variety of 
dermatological disorders. The most commonly used and most successful of them is 
Dexamethasone- Cyclophosphamide pulse (DCP) in Pemphigus vulgaris.  
A sample list of other pulse therapies is:  
DISEASE PULSE THERAPY 
Autoimmune blistering 
disease 
Dexamethasone -  Cyclophosphamide pulse 
Dexamethasone pulse 
Cyclophosphamide pulse  
Methyl prednisolone - Cyclophosphamide pulse 
Methyl prednisolone pulse 
Dexamethasone -  Azathioprine pulse  
Collagen vascular diseases Dexamethasone -  Cyclophosphamide pulse 
Cyclophosphamide pulse  
Methyl prednisolone – Cyclophosphamide pulse 
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Psoriasis vulgaris7 Methotrexate weekly pulse 
Vitiligo vulgaris8 Betamethasone oral mini pulse 
 Cyclophosphamide pulse 
Alopecia areata9 Dexamethasone pulse, 
Methylprednisolone pulse 
Pyoderma gangrenosum10 Cyclophosphamide pulse, 
 Dexamethasone -  Cyclophosphamide pulse, 
Air borne contact dermatitis11 Azathioprine weekly/ monthly pulse 
Acne vulgaris12 Azithromycin pulse 
 
GLUCOCORTICOID PULSE THERAPY:  
 In the context of corticosteroids, pulse therapy is defined as ‘treatment with 
more than 250mg of prednisolone or its equivalent per day, for one or more days’.13 
 The first pulse therapy used in Collagen vascular disease was 
methylprednisolone in 1976 for lupus nephritis.2  
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RATIONALE FOR GLUCOCORTICOID PULSE THERAPY: 
o The high dose of corticosteroids given as pulse therapy exerts an 
immediate and profound anti inflammatory effect. In comparison to 
oral glucocorticoids, pulse steroids have additional non genomic 
immediate effects which are responsible for the quicker onset of action. 
o Hence there is a faster clinical recovery symptomatically, as well as the 
inflammatory damage is minimised. 
o The clinical recovery after pulse therapy has known to last for3 weeks.   
o The toxicity has been consistently less compared to daily oral steroids in 
a number of studies. A case control study has shown that pulse 
glucocorticoids are not associated with more osteopenia or 
osteoporosis compared to high dose oral glucocorticoid therapy. This 
was also proved in another study done in rheumatoid arthritis patients. 
The cosmetogenic and diabetogenic effects of pulse steroids are less 
severe. 
o There is no prolonged suppressive effect on the hypothalamo pituitary 
adrenal (HPA) axis. Moreover pulse therapy helps in more rapid 
tapering of oral steroids when used concomitantly at the start of 
therapy.1 
o Therefore the risk benefit ratio of pulse therapy in comparison to daily 
oral steroid therapy is high. 
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METHYL PREDNISOLONE Vs DEXAMETHASONE: 
 Methylprednisolone is an intermediate acting steroid with a plasma half life of 
12-36 hours. It has low potency to cause sodium and water retention (glucocorticoid: 
mineralocorticoid effect is 6:1) compared to hydrocortisone.1It is given in the dose of 
15-30mg/kg body weight/day or 500-1000mg/m2 body surface area up to a maximum 
of 1g/day for 1-3 days.14 
 Dexamethasone is a fluorinated glucocorticoid. It is along acting agent with a 
plasma half life of 36-72 hours. It has negligible mineralocorticoid activity. Hence there 
is almost no sodium retaining tendency. It is given in a dose of 2-5mg/kg body weight 
for 3 days consecutively.15 
 There is no significant difference between the 2 drugs in terms of efficacy.  But 
the cost factor plays a crucial role in deciding between the two drugs. In the Indian 
context, dexamethasone would be more preferable since the cost of dexamethasone 
pulse therapy is only Rs.1085/patient compared to Rs 3660/patient with 
methylprednisolone for each pulse. The cost ratio of dexamethasone: 
methylprednisolone is roughly 1: 3. 
 In cases of brain edema when a drug with lower mineralocorticoid activity is 
preferred, Dexamethasone scores over methylprednisolone.1 
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MECHANISM OF ACTION OF PULSE STEROIDS: 
 Glucocorticoids have 4 main actions: anti-inflammatory, antiproliferative, 
vasoconstrictive and immunosuppressive properties.16 
 In collagen vascular disease, the anti-inflammatory and immunosuppressive 
properties are the main modes of action. 
 The cellular effects of steroids are mediated by 2 mechanisms: genomic and 
non genomic. 
GENOMIC EFFECTS: 
 For genomic effects, the glucocorticoid has to bind to its specific receptors 
which are located in the cytoplasm of cells called cytosolic glucocorticoid receptors 
(cGCR). 
 The cGCR is a complex of various heat shock proteins (hsp70 and hsp90) and 
has a zinc finger motif which is required for transcription. 
 The cGCR due to its interaction with various kinases like mitogen activated 
protein kinases (MAPK),immunophilins and co-chaperones such as p23 and src plays a 
role in cell signalling. 
 The steroid receptor complex then migrates to the nucleus together as a 
homodimer and bind to specific DNA sequences in the promoter region which are 
called glucocorticoid responsive elements (GRE). This activates transcription factors 
which can cause either the induction or inhibition of synthesis of specific regulator 
proteins. 
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TRANSACTIVATION: If there is an induction of synthesis due to binding of a positive 
GRE it is called transactivation. In a similar way, binding to a negative GRE can also 
lead to inhibition of transcription. In this way, various cytokines, chemokines and 
enzymes mediating inflammation and immune response are activated or inhibited. 
TRANSREPRESSION:Here the steroid receptor monomers directly interact with 
transcription factors without involvement of GREs. 
 For example, steroids can induce synthesis of IκB which can decrease the 
amount of NF – κB, which is proinflammatory, thereby decreasing the levels of 
cytokines induced by NFκB like IL 1, IL 6 and TNF α. 
 The genomic action is a slow process taking hours or days to see changes even 
at the cellular and tissue level. The effects of pulse therapy are too rapid to be 
explained by genomic events. 
NON GENOMIC EFFECTS: 
 This can be due to 3 modes of action. 
1) cGCR mediated non genomic effects: 
 Binding of glucocorticoids to cGCR leads to a rapid intracellular signalling via 
MAPK and co-chaperone src as mentioned above. 
2) Non specific non genomic effects: 
 This occurs at high glucocorticoid concentrations. Here the glucocorticoids 
intercalate into the cellular membranes, influencing cation transport across plasma 
membrane and increasing proton leak across the mitochondrial membrane. 
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 The ultimate result is decreased calcium and sodium cycling across the plasma 
membrane of immune cells leading to rapid immunosuppression and reduction of 
inflammatory process. 
3) Effects mediated by membrane bound glucocorticoids receptors: 
 GCR are also found on cell membrane and are called as mGCR. Activation of 
these receptors causes rapid induction of apoptosis and induction of lipomodulin 
which inhibits production of prostaglandins and leukotrienes. 
Buttergeit et al modules of glucocorticoid effect16 
1)  At low concentrations – genomic events 
2)  At moderate concentrations – bind to mGCR leading to cross membrane signal 
transmission for genomic and non genomic intracellular events. 
3)  At high doses – steroids dissolve into the cell membrane and result in greater 
membrane stability. 
Overall Glucocorticoid pulses causes 
- Down regulation of activation of immune cells and proinflammatory cytokines 
leading to reduced expression of adhesion molecules and decreased neutrophil 
chemotaxis. 
- These effects are similar to those seen with anti TNF α therapy. 
- It was found that a single high dose will lead to 100% saturation of cytosolic 
receptors, but this receptor occupation reverts back quickly unless a new dose 
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is given. Hence single high doses do not have sustained effects and 3 day pulses 
are preferred. 
 
MECHANISM OF ACTION OF GLUCOCORTICOIDS- Diagrammatic representation3
 
ADVERSE EFFECTS OF GLUCOCORTICOID PULSES: 
Overall incidence of adverse effects may be low, partially because they allow 
more rapid tapering of oral glucocorticoid doses.17Complications due to large dose and 
route of administration are 
1)  Fluid overload  
2)  Hypertension - due to rapid flux in electrolytes 
3)  Neuropsychiatric symptoms – mood alteration, sleep disturbances, psychosis  
                                          - commonly seen in 10% of patients. 
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Rare complications: 
1)  Cardiac arrhythmias 
               It can also occur several days after therapy. It is due to rapid administration of 
large doses. Hence slow administration over 2 – 3 hours should be given.      
2)  Sudden death 
3)  Bradycardia – unrelated to speed and duration of infusion. 
4)  Intractable hiccups44 
Others: 
Hypokalemia, Hyperglycemia, Infections, Glaucoma, Cataract, Acne, diarrhoea, 
weakness, muscle pains, facial flushing, weight gain. 
PRECAUTIONS: 
Before starting therapy 
1)  Rule out systemic infection 
Minor URI, skin infection and gastroenteritis are not a contraindication for 
therapy 
2)  Rule out malignant hypertension 
Mild and moderate hypertension must be controlled by appropriate drugs. 
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During treatment 
- Recording of heart rate(HR), respiratory rate (RR) and blood pressure(BP) every 
15 – 30 minutes 
- If arrhythmia is suspected, infusion is to be stopped immediately. ECG and 
serum electrolyte abnormalities are to be corrected. 
- Estimation of blood sugar and electrolytes every alternate day.1 
 
CYCLOPHOSPHAMIDE IN PULSE THERAPY 
 Cyclophosphamide is nitrogen mustard. It was first described by Arnold and 
Bourseaux. It is a widely used chemotherapeutic agent.  
 It is an alkylating agent widely used in cancer chemotherapy. It is a prodrug. In 
the liver it gets activated into two metabolically active compounds by cytochrome 
P450. The first compound 4-αhydroxycyclophosphamide is responsible for its anti 
cancer activity. Chloroacetaldehyde or aldophosphamide, the second metabolite 
produced by side chain oxidation is in turn converted into phosphoramide mustard 
(active), carboxyphosphoramide (inactive) and acrolein. Phosphoramide mustard is 
responsible for its immunosuppressive effects. Acrolein is the culprit metabolite 
behind haemorrhagic cystitis.18 
 The active principle- phospharamide mustard undergoes cyclization to a 
reactive aziridium intermediate, causes alkalinisation of guanosine bases of DNA 
resulting in cross linking of DNA, abnormal base pairing, imidazole ring cleavage with 
depurination and chain scission. This produces inhibition of DNA replication, leading to 
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cell death. It acts on both resting and dividing lymphocytes. On T cells, it specifically 
causes inhibition of suppressor Tcells than T helper cells. The effect on B cells is more 
prolonged since B cells take more time to recover from the suppression induced by an 
alkylating agent.  
ADVERSE EFFECTS: 
1. Haematological:  It produces myelosuppression especially leucopenia. The 
nadir commonly develops 8-12 days after initiation of therapy. It is a dose 
limiting side effect. Thrombocytopenia and anaemia are less frequent. 
2. Urological damage:  Haemorrhagic cystitis is the most important urological 
complication. The principle metabolite producing this condition is acrolein.  It 
also produces increased frequency, urgency, dysuria,microscopic hematuria, 
bladder telangiectasias, bladder fibrosis and vesicouretral reflux. 
3. Gonadal damage: In males it causes azoospermia by depletion of testicular 
germ cells, whereas in females, disappearance of primordial follicles results in 
premature ovarian failure. The dose of cyclophosphamide required to produce 
gonadal failure is dependent on the age of the patient. For females, in their 
20s, 30s, 40s, the cumulative dose required is 20, 10, 5 g respectively.19The 
benefits of using testosterone in males and leuprolide acetate in females to 
prevent gonadal failure are not fully known. Cryopreservation of reproductive 
material can be offered to patients if adequate resources are available. 
4. Gastrointestinal toxicity: Nausea and vomiting are very common side effects. 
They can be easily controlled by antiemetics like ondansetron. 
21 
 
5. Carcinogenesis: Transitional cell carcinoma of renal pelvis, ureter and bladder, 
non-Hodgkin’s lymphoma, acute leukaemias and squamous cell carcinomas can 
occur.20 
6. Cutaneous toxicity: Anagen effluvium, hyper pigmentation of nails and skin, 
mucositis, acral erythema and persistent pigmented band over teeth are 
common complications. 
7. Teratogenicity: If given in the first trimester of pregnancy. 
Pulse cyclophosphamide generally has less urological side effects compared to 
oral Cyclophosphamide because of ensurance of hydration in in-patients. 
CONTRAINDICATIONS: 
ABSOLUTE: Hypersensitivity. 
RELATIVE: 
Pregnancy 
 Lactation 
 Bone marrow suppression: Leucocytes less than 3000 cells/cubic mm, Platelet 
count less than 1 lakh cells/cubic mm. 
 Transitional cell carcinoma of bladder.18 
 Impaired hepatic/ renal functions. 
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PRECAUTIONS: 
Ensure adequate hydration of 2-3 litters/day while on cyclophosphamide pulse 
therapy. 
Before starting cyclophosphamide pulse rule out infections e.g. Latent 
Tuberculosis  
DEXAMETHASONE –CYCLOPHOSPHAMIDE PULSE THERAPY: 
  Initially, only dexamethasone pulses were used. Cyclophosphamide boluses were 
added because relapses were frequent with dexamethasone alone. The combination of 
cyclophosphamide and dexamethasone has synergistic effect. This synergy is observed 
only with high dose cyclophosphamide and not with low doses.21The addition of 
cyclophosphamide improves the outcome of renal and pulmonary disease activity. In 
patients who are unmarried only I.V.dexamethasone with daily 50mg azathioprine 
without any bolus is given (DAP pulse).  
PHASES OF PULSE THERAPY:  
 There are 4 phases in the Dexamethasone cyclophosphamide pulse therapy for 
collagen vascular diseases.     
Phase I: 3 days of I.V. Dexamethasone (100 mg) in 500ml of 5% dextrose with I.V. 
Cyclophosphamide (500 mg) on the first day. Pulses are repeated once in 28 days. In 
between pulses only tablet cyclophosphamide 50mg is given. This phase lasts up to 
remission of the disease process (clinical or laboratory). 
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Phase II: Lasts up to 6 months after clinical remission 
Phase III: Only 50mg oral cyclophosphamide is given for 1 year. 
Phase IV: Follow up without any treatment for 2-3 years. 
If there is any relapse of disease activity in phase II OR III, then the patient 
enters phase I again. The same regimen is followed in Pemphigus vulgaris, but the 
duration of phase II is 9 months.22 
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
DEFINITION: A systemic disease characterised by multisystem organ inflammation, 
most commonly the skin, joints and vasculature, and associated immunological 
abnormalities. 23 
REVISED AMERICAN RHEUMATISM ASSOCIATION (ARA) CRITERIA FOR DIAGNOSIS OF 
SLE (1982) 
1.  Malar rash-  
 Fixed erythema, flat or raised over malar eminence, sparing the nasolabial fold. 
2.  Discoid rash-  
 Erythematous raised patches with adherent keratotic scaling & follicular 
plugging; atrophic scarring occurs in older lesions. 
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3.  Photosensitivity-  
 Skin rash as a result of unusual reaction to sunlight, obtained by patient history 
or physician observation. 
4.  Oral ulcers-  
 Oral or nasopharyngeal ulcers; usually painless; observed by physicians. 
5.  Non erosive arthritis-  
 Non erosive arthritis involving two or more peripheral joints and is 
characterized by swelling or effusion. 
6.  Serositis-  
 Pleuritis: Convincing history of pleural pain, pleural rub or evidence of pleural 
effusion 
               Pericarditis- ECG, pericardial rub or evidence of pericardial effusion. 
7.  Renal disorder-  
 Persistent proteinuria of more than 0.5g/d or more than 3+; 
 Cellular casts in urine-RBC, Haemoglobin, granular, tubular or mixed casts. 
8.  Neurological disorder-  
 Seizures- in the absence of drugs, metabolic derangement, diabetic 
ketoacidosis (DKA), uremia or electrolyte imbalances. 
 Psychosis. 
25 
 
9.  Haematological disorder- 
 Hemolytic anemia with reticulocytosis 
 Leucopenia:  <4000c/mm on 2 or more occasions 
 Lymphopenia:  <1500c/mm on 2 or more occasions 
 Thrombocytopenia: < 1 lakh c/mm in the absence of offending drugs 
10.  Immunological disorder- 
 Anti ds DNA antibodies  
 Anti Sm antibodies 
 Antiphospholipid and anticardiolipin antibodies, lupus anticoagulant. 
 False positive serological test for syphilis (STS) i.e. VDRL for more than 6months 
11.  Antinuclear antibodies- 
 Abnormal titers of ANA by immunofluorescence (IF) in the absence of drugs 
known to be associated with drug induced lupus syndrome. 
Presence of 4 or more of the above criteria either simultaneously or 
sequentially is a pre requisite for diagnosis. 
It is 96% sensitive & 96% specific.23 
PATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS: 
 The basic pathology in SLE involves a complex interplay of host factors and 
environmental factors, leading to a loss in immune tolerance. This results in 
26 
 
production of auto antibodies directed against the patient’s own nucleosomes and 
RNAs. The evolution of disease process consists of 4 phases 
1. Susceptibility: The inherent HLA type, complement deficiencies, Gene 
polymorphism for TNF α increase the susceptibility of the individual. 
2. Induction phase: Environmental factors lie V radiation, viruses , drugs and 
tobacco induce apoptosis and triggers antigen processing by dendritic cells. 
3. Expansion phase: Stimulation of immune system results in Tcell expansion and 
B cell proliferation with the end result of autoantibody formation. 
4. Injury phase: The ultimate end result is tissue damage caused by deposition of 
immune complexes and cytotoxic T cells along with release of numerous 
inflammatory mediators.24 
The role of pulse therapy of dexamethasone and cyclophosphamide is at the level 
of expansion and injury phase. By the immunosuppressive potential both the drugs 
inhibit T cell proliferation resulting in decreased production of cytokines like TNF α, 
IFNα other inflammatory mediators. T cell mediated activation of auto reactive B cells 
is suppressed resulting in decreased production of auto antibodies. 
CLINICAL EVALUATION OF SLE PATIENTS: 
 Objective evaluation of disease activity in Lupus Erythematosus can be done by 
various methods like CLASI, SLEDAI, and BILAG etc.23 
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CUTANEOUS LUPUS DISEASE AREA AND SEVERITY INDEX (CLASI) 
 Cutaneous Lupus Disease Area and Severity Index (CLASI) were developed in 
the Jefferson Medical College, Philadelphia25. It measures the cutaneous disease 
activity and residual damage separately.  
 The body surface is divided into 13 areas with increased weightage being given 
to the most commonly affected sites like the nose including malar area, ears, posterior 
neck and shoulder. The content validity of CLASI has been assessed by American 
College of Rheumatology and was found to be of adequate validity.  
ADVANTAGES OF CLASI: 
1. Disease activity and damage are scored separately. If on the other hand a 
cumulative score of the area affected would have been measured, it would 
have resulted in stable scores with scarring Lupus, although the activity may be 
decreasing. 
2. Ease of administration. 
3. Non reliance on invasive tests. 
DISADVANTAGES OF CLASI: 
1. It does not take into account the systemic disease activity which may not 
correlate with the cutaneous activity.  
2. Other cutaneous lesions such as bullous lesions, livedoreticularis etc. are not 
included in the scoring. 
28 
 
CLASI SCORING 
ANATOMICAL 
LOCATION 
ERYTHEMA 
0-Absent 
1-Pink, faint 
2-Red 
3-Dark 
red/purple/crus
ted 
Hemorrhagic 
SCALE/ 
HYPERTROPHY 
0-Absent 
1- Scale 
2- Veruccous/ 
hypertrophic 
DYSPIGMENTA 
-TION 
0-Absent 
1-
Dyspigmentation. 
SCARRING/ATROPHY
/ 
PANNICULITIS 
0-Absent 
1-Scarring  
3-Severely atrophic 
scarring or 
panniculitis 
 
Scalp     
Ears     
Nose(including malar 
area) 
    
Rest of face     
V area of neck     
Past. Neck& Shoulder     
Chest     
Abdomen     
Back, Buttocks     
Arms     
Hands     
Legs     
Feet     
 
MUCOUS MEMBRANE DYSPIGMENTATION 
0-Absent                                                          1-Lasts less than 12 m 
1-Present2-Lasts more than 12 m 
ALOPECIA 
Recent Hair loss 
(within the last 30 days/as reported by patient)  
Scarring 
0-No 
1-YES 
 NB: if scarring and non-scarring aspects 
seem 
to coexist in one lesion, please score both 
ALOPECIA(clinically not obviously scarred) Scarring of the scalp (judged clinically) 
0-absent 
1-diffuse; non-inflammatory 
2-focal or patchy in one quadrant; 
3-focal or patchy in more than one 
quadrant 
 0- absent 
3- in one quadrant 
4- two quadrants 
5- three quadrants 
6- affects the whole skull 
 
Total Activity Score:                                                     Total Disability Score: 
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SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) 
 This is a complex scoring system taking into account systemic symptoms, 
cutaneous manifestations and laboratory parameters. Since this scoring also takes into 
account complement levels, such a scoring may not be possible in resource poor 
settings.26 
LABORATORY MONITORING OF DISEASE ACTIVITY 
 Apart from usual parameters such as Erythrocyte sedimentation rate (ESR) and 
C- reactive protein, in SLE antidsDNA antibody levels and complement levels are 
known to correlate with disease activity. 
 Anti dsDNA test was incorporated in the 1982 revised American College of 
Rheumatology criteria for the diagnosis of SLE. Apart from diagnosis, it also aids in 
monitoring disease activity and determining the prognosis. The anti dsDNA antibodies 
can be eluted from experimental animals and human kidneys affected by lupus 
nephritis. Serum anti dsDNA levels is at high titres during proliferating lupus nephritis 
and they are more likely to play in role in its development.27 
 Recent reports also suggest anti dsDNA may have a role in neurological disease 
by its ability to bind to NR2 glutamate receptors inducing neuronal apoptotic death. 
But, there is a weak correlation with skin disease activity.28 Also, the role of anti 
dsDNA in other clinical manifestations is not entirely studied.A high binding capacity is 
associated with poor prognosis.Anti dsDNA can be measured using various techniques 
such as the ELISA and immunofluorescence  which are economical  compared to the 
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Farr technique which measures the high avidity more pathogenic  radio labelled anti 
dsDNA. 
 Antinuclear antibody levels do not correlate with disease activity. 
SYSTEMIC SCLEROSIS 
DEFINITION: It is a multisystem disorder characterized by the association of vascular 
abnormalities, connective tissue sclerosis and atrophy and auto antibodies.29 
SUBCOMMITTEE OF SCLERODERMA CRITERIA OF THE AMERICAN 
RHEUMATISM ASSOCIATION 
Major criteria: 
 Scleroderma proximal to the digits, affecting limbs, face, neck or trunk. 
Minor criteria 
a) Sclerodactyly 
b) Digital pitted scars 
c) Bilateral basal pulmonary fibrosis. 
1 major and any 2 minor criteria should be present for diagnosis. 
It has 97% sensitivity and 98% specificity.29 
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CLASSIFICATION OF SYSTEMIC SCLEROSIS: 
DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: 
 Short interval (less than 1 year) between the onset of Raynaud’s phenomenon 
and the development of skin changes. 
 Truncal and peripheral skin involvement 
 Tendon friction rubs 
 Pulmonary fibrosis, renal failure, gastrointestinal disease, myocardial 
involvement. 
 Capillary drop out visible in nail folds.  
 Scl-70 antibodies. 
 Anticentromere antibody negative. 
LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: 
 Long history of Raynaud’s phenomenon 
 Limited skin involvement only 
 Calcification, telangiectasia, late onset of pulmonary hypertension 
 Capillary dilatation visible in nail folds without drop outs. 
 Anticentromere antibody positivity.30 
PATHOGENESIS OF SYSTEMIC SCLEROSIS: 
 Similar to SLE in scleroderma the host and environmental factors act in 
conjuncture to stimulate an autoimmune process and endothelial damage. One of the 
early events in the pathogenesis is an immunological trigger of T cells. Macrophages, 
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mast cells and platelets. These in turn elaborate various cytokines, adhesion molecules 
and growth factors which results in the expansion of fibrogenic clones of tissue 
fibroblasts. These clones of fibroblasts over express genes encoding for extracellular 
matrix components and behaves in a relatively autonomous way.32 
 The end result is an excessive deposition of collagen and other connective 
tissue matrix proteins  within blood vessel wall resulting in vasculopathy (Raynaud’s 
phenomenon), in the skin producing hide bound skin, mask like facies and difficult 
mouth opening and in the internal organs producing dysphagia, restrictive lung disease 
etc. 
CLINICAL EVALUATION OF SYSTEMIC SCLEROSIS DISEASE ACTIVITY: 
SKIN SCEROSIS MEASUREMENT:  
 The concept of using a skin score was first sowed by Farmer et al (1960) and 
Barnett et al (1969)  who in their separate studies noted that extensive skin change 
was associated with major visceral involvement in SSc. Since then several studies have 
demonstrate that the outcome in scleroderma is associated with baseline skin score. 
The change in skin score reflects the severity of visceral involvement and determines 
the prognosis. 
 The most popular score was the Rodnan skin score (RSS) introduced in 1979. 
Here biopsies the skin thickness is measured from 26 sites by measuring the net 
weight and dry weight. The skin thickness was measured in grades from 0 to 4. It has 
undergone various modifications as follows: 
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22 site modified RSS (0 to 3, maximum 66) –Kahaleh et al in 1986  
–10 site modified RSS (0 to 3, maximum 30) –Clements et al in 1990 
–17 site modified RSS (0 to 3, maximum 51) –Clements et al in 1993 
Modified Rodnan scoring now measures the skin score from 17 sites rather 
than 26. Skin thickness rather than tethering is assessed. Limited cutaneous disease 
and overlap syndromes can be especially challenging. Influence of co-morbidity 
including soft tissue swelling, loss of subcutaneous fat, skin oedema interferes with 
accurate assessment. 
Durometry: It was first developed by Falanga and Bucalo in1993.  
Elastometry: It was developed by Balbir-Gurman et al in 2002. It is a non-invasive 
measurement of biomechanical skin properties in systemic sclerosis.  
Ultrasound: Ultrasound for measurement of skin thickness in scleroderma was first 
introduced by Moore TL et al in 2003.A seventeen-point dermal ultrasound scoring 
system was developed which is a reliable measure of skin thickness in patients with 
systemic sclerosis. It also has the advantage of being non invasive.33 
HIDEBINDING/ TETHERING SKIN SCORE OF FURST et al: 
 In comparison to the Modified Rodnan skin score and other methods a rather 
simple scoring and dependent only on clinical findings and not on histopathology was 
developed by Furst et al. 
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0- Skin not tethered or bound down. 
1- Mild tethering 
2- Moderate tethering 
3- Severe tethering 
10 skin sites are examined which are the face, back, chest, abdomen, arms, 
forearms, hands, thighs, legs and feet. The sum total of all points at all sites is the skin 
score. The maximum score is 30.34 
EVALUATION OF SYSTEMIC INVOLVEMENT: 
 The pulmonary function tests, radiological changes in HRCT like ground glass 
appearances have been used to measure lung involvement. Renal involvement is 
measured by serum creatinine, creatine clearance and 24 hour urine protein. 
Gastrointestinal involvement is assessed clinically by degree of dysphagia and by 
oesophageal manometry. Involvement of other systems like cardiac (ECG, 
echocardiogram) and musculoskeletal system (muscle enzymes) are also assessed. 
PULSE THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS &  
SYSTEMIC SCLEROSIS 
 The first pulse therapy in SLE was the use of methylprednisolone for lupus 
nephritis in 1976. Consequently methyl prednisolone pulse was used by Isenberg for 
recalcitrant cases of SLE. Methylprednisolone along with cyclophosphamide pulse 
therapy was studied by Hu J et al35 and reported clinical remission after 8-10 pulses. 
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 Dexamethasone along with cyclophosphamide in pulse therapy has been 
mainly used by Indian physicians. Dhabhai ET al5 along with Garg et al reported 
cutaneous remission in most patients. Gupta ET al36 used DCP in a single SLE patient 
and reported remission in 11 pulses. Sudip ET al48 reported 75% improvement in all 
cutaneous manifestations by 4 pulses. Similar results were obtained by S Parajauliet 
al37 in 5 patients.  
 The earliest documented evidence of pulse therapy in systemic sclerosis was in 
1982 by Isenberg et al who used methyl prednisolone pulse therapy. Pulse therapy 
again came into prominence when Dexamethasone pulse was shown to produce 
remission in a 22 year old patient by J S Pasrischa et al in 1990.38Although there have 
been controversies regarding the precipitation of renal crisis by high dose steroids, it 
has been refuted in various Indian reports by Ramam B et al andPai BS et al.39 
 In a prospective study conducted by Ahmed et al, pulse therapy was shown to 
halt the disease progression when started early in the course of the disease with 
improvement in skin sclerosis, pulmonary function tests, ESR and histopathological 
examination of the skin.6 None of the patients involved in his studied showed any 
relapse or reversal of the improvement achieved after being put of on pulse therapy. 
  Dexamethasone pulse therapy alone without cyclophosphamide was used by   
Pasricha et al., where he observed that around 12-21 pulses were needed to achieve 
clinical remission.38 Similar studies conducted by Gupta et al and Ahmed et al 
recommend 12-18 pulses for clinical improvement.39 They also observed that 
pulmonary functions improved with 4-6 pulses itself. Sharada et al. used a shorter 
duration of pulse therapy for 6 months and made an observation that such courses 
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produce clinical improvement of skin scores alone40.Griffith evaluated the use of i.v. 
cyclophosphamide and methylprednisolone for 6 pulses and the modified rodnan skin 
scoring improved by 35%. Pakas et al observed that the effect of I.V cyclophosphamide 
in reducing skin score was significant when given along with high dose steroids41. 
Along with low dose steroids, the results obtained were not that significant.  
 Airo et al. used intravenous cyclophosphamide alone for active alveolitis for a 
period of six months and found that it produced significant improvement in pulmonary 
function tests. Barbara et al. performed a large scale study in 103 patients with 
alveolitis by administering i.v. as well as daily oral cyclophosphamide for 12-18 months 
and observed marked improvement of PFT42. Vatwani et al. used pulse therapy in a 
paediatric patient and observed that eight pulses of dexamethasone along with i.v. 
cyclophosphamide without oralcyclophosphamide is effective.43 
 Side effects peculiar to pulse therapy include hiccups44, facial 
flushing46, diarrhoea, weakness, generalized swelling and weight gain, joint and muscle 
pains. This was reported by Verma KK and Kanwar AJ et al. These side effects are 
usually observed with each pulse and last for a few days afterwards.Most patients are 
able to tolerate these symptoms and continue treatment45.  
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MATERIALS AND METHODS 
TYPE OF STUDY:  
 This is a type of open labelled non randomised prospective therapeutic study. 
Here the patients act as their own control. 
SAMPLE SIZE: 
 A sample size of 36 patients was selected. Out of these, 20 patients had 
systemic lupus erythematosus and the other 16 had Systemic Sclerosis.  
 
STUDY PLACE: 
 
 This study was conducted at the Department of Dermatology, Stanley Medical 
College in association with other departments for evaluation of systemic involvement. 
 
STUDY PERIOD:  
 The study was conducted over a period of 2 years from November 2009 to 
October2011. 
 
PATIENT SELECTION CRITERIA: 
INCLUSION CRITERIA: 
1. Systemic lupus erythematosus and systemic sclerosis patients diagnosed as per 
ARA criteria. 
1. Age: 13 to 60 years. 
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2. Severe skin lesions not responding to high dose daily steroids 
3. Presence of systemic involvement. 
 
EXCLUSION CRITERIA: 
1. Pregnancy. 
2. Lactating mothers. 
3. Children <12 years. 
4. Ischemic heart disease. 
5. Uncontrolled hypertension. 
6. Active infections except Minor upper respiratory tract infections, acute 
gastroenteritis and skin infections. 
 
PROCEDURE: 
The patients were selected according to the inclusion criteria. A detailed 
history and physical examination was done. The following investigations were done 
prior to starting pulse therapy. 
Diagnostic tests 
 Skin biopsy, ANA, Anti dsDNA 
Tests to find out systemic involvement: 
 Renal: Blood urea, serum creatinine, urine routine & 24 hour urinary protein. 
 Cardiac: ECG, Echocardiogram. 
 Pulmonary: X ray chest, pulmonary function tests. 
 G.I: Barium swallow, OGD scopy. 
 CNS: EEG, CT scan brain. 
 Musculoskeletal: Creatine phosphokinase (CPK). 
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 Hematological: Complete hemogram, platelet count, peripheral smear. 
Tests to assess fitness for pulse therapy: Mantoux, blood sugar, pregnancy tests in 
females. 
Informed consent & photographs. 
 
ADMINISTRATION OF PULSE THERAPY: 
 The patients selected are hospitalised a day before the pulse therapy. Pre pulse 
investigations such as blood sugar, urea, serum creatinine, electrolytes, liver function 
tests, complete hemogram and urine routine are taken during each cycle. If all 
parameters are normal the pulse therapy is administered. Injection dexamethasone 
100mg in 500ml of 5% dextrose by slow intravenous infusion over 2-3 hours is given 
for 3 consecutive days. On day 1, injection cyclophosphamide 500mg is also added. On 
rest of the days only tablet cyclophosphamide 50 mg per day is given. In young 
unmarried patients and those who have not completed their family only injection 
dexamethasone is given. On the rest of the days, oral azathioprine 50 mg per day is 
given. In patients with diabetes millets 8 U of regular Insulin was added into the 5% 
dextrose solution.  
 
 Pulse rate, blood pressure and ECG will be monitored before start of the 
infusion. Intermittent monitoring of pulse and blood pressure is done every half an 
hour during the infusions. The electrolytes and blood sugar are measured after the 
end of pulse therapy. If all parameters are normal the patient is discharged the next 
day.The next pulse is repeated after 28 days. In SLE patients in addition oral 
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chloroquine 250mg per day is given. In systemic sclerosis patients, vasodilators 
(nifedipine 10mg t.d.s) are given in all patients.  
 
PRECAUTIONS: 
 All patients were instructed to maintain a daily fluid intake of 2 L to prevent the 
development of hemorrhagic cystitis. 
 Calcium supplements (1500mg/day) were given to all patients to prevent the 
development of osteoporosis 
 During the 3 days of pulse therapy, potassium chloride syrup was given to 
minimise the risk of development of hypokalemia 
 Ophthalmic examination was done before the start of therapy and every 6 
months to rule out glaucoma and posterior sub capsular cataract. 
 
EVALUATION OF RESPONSE: 
 In systemic lupus erythematosus, disease activity was evaluated by measuring  
 CLASI score  for cutaneous improvement, 
 Clinical assessment of improvement in malar rash, photosensitivity, discoid 
rash, alopecia, oral erosions, fever, joint pain and symptoms pertaining to 
other system involvement. 
 Laboratory monitoring of renal function tests including blood urea, serum 
creatinine and 24 hour urinary protein, 
 Total and differential counts,  
 Erythrocyte sedimentation rate (ESR) 
 ANA titre 
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 Anti dsDNA titre  
In systemic sclerosis, disease activity was evaluated by measuring 
 Skin tightening measurement using Hide binding/ tethering skin score of Furst 
et al 
 Clinical evaluation of Raynaud's phenomenon, digital ulcers, pigmentary 
alterations 
 Symptoms pertaining to other system involvement. 
 Pulmonary function tests and renal function tests including blood urea, serum 
creatinine and 24 hour urinary protein 
 ESR 
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RESULTS 
IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS 
 A total of 20 SLE patients were recruited in the study group for pulse therapy. 
The results at the end of a minimum of 8 pulses is discussed 
 
AGE DISTRIBUTION: 
 Of the twenty patients the youngest was 17 years old and the oldest was 34 
years old. The highest number of patients (30%, 6 patients) were in the age group of 
20-25 years. The mean age of the patients was 23.2 years. The age distribution is 
represented graphically in figure 1. 
 
SEX DISTRIBUTION: 
  The study group included 19 females and 1 male, with a female: male ratio of 
I9:1.  
 
DURATION OF ILLNESS: 
 The average duration of illness of the patients included in the study before 
pulse therapy could be initiated was 16.5 months. The shortest duration was 2 months 
in patient no.4 to 42 months in patient no.20.  
 
CUTANEOUS MANIFESTATIONS 
 Only those patients who had skin manifestations were included in this study. 
The relative distribution of cutaneous features are: discoid rash in 100%, malar rash in 
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85% (17 patients), photosensitivity in 95% (19 patients), oral erosions in 90% (18 
patients), and alopecia in 85%. Other manifestations seen were livedoreticularis in 1 
patient (patient no.6) who also had neurological manifestations; bullous lesions seen 
in one patient (patient no.5) urticarial vasculitis in 1 patient (patient no.2) who had 
vasculitis retina and vasculitic ulcers were seen in 3 patients. The prevalence of skin 
manifestations is representated in figure 2. 
 
CUTANEOUS LUPUS AREA AND SEVERITY INDEX (CLASI): 
 The activity score of CLASI, was between 12 and 34, out of a total score of 70 at 
the initiation of treatment. There was a fall in the CLASI activity scores in all the 20 
patients at the end of 8 cycles of pulse therapy. The final CLASI activity score was 0 in 5 
patients (25%). In 13 other patients (65%) the CLASI activity score recorded a marked 
fall to a score of less than 5. In 2 patients (10%) alone there was a score of more than 
10.  
 The difference in the CLASI activity scores before the initiation of pulse therapy 
and after the completion of 8 pulses were analysed using the paired‘t’ test. 
 Standard deviation (S.D) = 5.785 
 Standard error of difference (S.E) = 1.294 
 The final t value was 17.85. 
The probability of error (p value) for the given t values with a degree of 
freedom of 19 was less than 0.005.  
 
 Since the probability of error was very low (p< 0.05), the difference in the CLASI 
activity before and after the pulse therapy was statistically significant.  
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 Whereas the activity score showed significant improvement in all but two 
patients, the damage score showed a different picture. The damage score which 
measures the residual dyspigmentation and scarring showed an initial increase in 
some patients as the disease activity subsided and the malar and discoid rashes left 
behind dyspigmentation and so did the mucosal erosions. The dyspigmentation took a 
long time to improve and seemed unrelated to the number of pulses. 
 
 The overall cutaneous response in each patient as quantified by the Cutaneous Lupus 
Area and Severity Index (CLASI) is as shown in the figure 3. 
 
PHOTOSENSITIVITY: 
 A history of photosensitivity was noted in all but on patient which is 95% of the 
study population. At the end of 8 cycles of pulse therapy, photosensitivity disappeared 
in all but 3 patients (15%)  
 
MALAR RASH: 
 The characteristic malar rash was present in 17 out of the 20 patients (85%).At 
the end of 8 pulses, there was complete disappearance of malar rash in 14 patients 
with percentage improvement of 82%.  
 
 
46 
 
 
0 5 10 15 20 25 30 35
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
CLASI ACTIVITY SCORES
P
A
TI
EN
T 
N
U
M
B
ER
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
After 8th pulse 3 3 1 2 3 0 1 20 0 2 11 1 2 3 3 0 0 2 3 0
Before 1st pulse 18 29 32 28 31 20 12 34 24 27 27 32 30 21 32 19 27 24 32 26
CLASI ACTIVITY SCORING IN RESPONSE TO 
PULSE THERAPY
After 8th pulse
Before 1st pulse
47 
 
DISCOID RASH: 
 Discoid rash was the most common manifestation presenting in 100% of the 
patients at the start of pulse therapy. At the end of 8 pulses,7 patients (35%) had 
complete disappearance of the discoid rash. In the rest of the patients there was 
moderate improvement with lesions showing minimal scaling in 11 patients (55%). 
There was a persistence of discoid rash in only 2 patients (10%). 
 
ORAL EROSIONS: 
 At the initiation of the study, oral erosions were present in 18 out of the 20 
patients (90%). At the end of 8 cycles of pulse therapy there were persistent erosions 
only in 2 patients with percentage improvement of 88%. 
 
ALOPECIA: 
 Alopecia was seen in 17 out of the 20 patients (85%). There was diffuse 
alopecia in all 17 patients, whereas lupus hair was seen in 6 patients. At the end of 8 
cycles of pulse therapy, clinically appreciated alopecia was seen in 3 patients. Alopecia 
improved in 14 patients with a percentage improvement of 82%. 
 
 The overall improvement of individual cutaneous feature with pulse therapy is 
represented graphically in figure 4. 
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FEVER: 
 At the initiation of pulse therapy, fever in the absence of any focus of sepsis 
was recorded in all but 4 patients who comprise 80% of our study population. Fever in 
most cases was of low grade and intermittent in nature. With the completion of 8 
pulses, fever was noted in 2 patients (10%). Both the patients initially became afebrile 
soon after the first pulse, but it reappeared after the 6th pulse in one patient and after 
the 7th pulse in another.  
 
SYSTEMIC MANIFESTATIONS: 
 All but 3 patients had systemic manifestations before the initiation which 
amounted to 85% of the study population. The most common systemic manifestation 
was joint involvement with non erosive arthritis being reported in 80% (16 patients), 
followed by renal involvement in 35% (7 patients). 6 patients (30%) had neurological 
involvement, of which 5 of them had seizures whereas one patient had altered 
behaviour and she went on to develop seizures after the pulse. There was vasculitis in 
5 of the patients(25%) of which 2 patients (10%) had retinal vasculitis and presented 
with diminished vision. The rest 3 patients had vasculitic ulcers. There was serositis in 
one patient (5%). Similarly, pulmonary involvement with interstitial pneumonitis was 
reported in one patient (5%) before the start of pulse therapy. 
  At the end of 8 cycles of pulse therapy, 5 patients (25%) continued to have 
systemic manifestations. Feverand arthralgia were present in 2(10%), renal and CNS 
involvement in 3 patients and vasculitis in 1 patient.  One patient newly developed 
interstitial lung disease after 7 pulses.   
50 
 
 
 
Figure 4 
0
2
4
6
8
10
12
14
16
Fever Arthritis Renal CNS
Vasculitis
N
o
 o
f 
p
at
ie
n
ts
SYSTEMIC FEATURE
Fever Arthritis Renal CNS Vasculitis
Series 1 16 16 7 6 5
Series 2 2 2 3 3 1
IMPROVEMENT OF SYSTEMIC MANIFESTATIONS 
WITH PULSE THERAPY
51 
 
ANTI dsDNA LEVELS: 
 All the patients except one (95%) showed positivity for anti dsDNA as 
measured by the immunofluorescence technique. The anti dsDNA values were 
quantified in serial dilutions. It was of low titres up to 1 in 40 in six patients (30%). In 
four patients (20%) there was a very high titre positivity of 1 in 1280. The other nine 
patients (45%) had moderate titres ranging from 1 in 160 to 1 in 640. 
 
 After 8 cycles of pulse therapy there was a fall in titres in all patients excluding 
two (10%) whose titres remained at very high levels of 1 in 1280 dilutions. Anti dsDNA 
antibody became negative in 6 patients (30%).  The fall in titres was by 2 to 4 folds in 
most other patients. Of these, 10 patients (50%) had low titres of upto 1 in 40 
dilutions. 3patients (15%) continued to have moderate values. 
 
 Overall, 2 patients (10%) had a static titre of anti dsDNA antibodies. The rest 
(90%) showed a fall in titre. No patient showed increase in anti dsDNA antibody titres. 
 
 The anti dsDNA levels before and after 8 pulses was statistically analysed using 
the paired‘t’test.  
The mean of variance was 319; the standard error of the difference was 92.516. The 
final t value was 3.45. The p value for the given t values and degree of freedom was 
less than 0.005, hence the difference between the 2 groups was statistically 
significant. 
 
 Hence there was a statistically significant fall in the anti dsDNA levels after 8 
pulses. 
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ANTINUCLEAR ANTIBODIES (ANA): 
 The anti nuclear antibody showed very high levels 1:1280 in 2 patients, high 
levels (> 1: 160) in 7 , moderate levels ( 1: 80) in 2 patients and low levels (1:40 & 1:10)  
in 10 patients. So at the start of pulse therapy 50% of patients had low levels, 10% of 
patients had moderate levels, high levels in 35% and very high levels in 10%. 
 
 After 8 pulses ANA was negative in 4 patients (20%), low levels in 14 patients 
(60%), and moderate levels in 2 patients (10%). 
 
 The most common pattern observed was rim or peripheral pattern in 9 
patients (45%) followed by homogenous pattern in 8 patients (40%) and speckled 
pattern in 3 patients (15%). 
 
 There was no absolute correlation between the disease activity and antinuclear 
antibody levels. Also the pattern of ANA did not influence the response to pulse 
therapy.   
 
ERYTHROCYTE SEDIMENTATION RATE: 
 
 At the initiation of pulse therapy ESR was elevated in 15 patients (75%). At the 
end of 8 pulses it remained elevated in 5 patients. The percentage improvement was 
66%. The ESR values had good correlation with systemic disease activity than 
cutaneous disease activity. 
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TOTAL LEUCOCYTE COUNT: 
 There was no significant decrease in total leukocyte count in any of the 
patients at the initiation of pulse therapy. There was no correlation with disease 
activity and total leukocyte count. 
 
DURATION TAKEN FOR CLINICAL REMISSION: 
 
  All the cutaneous features showed improvement with pulse therapy, showing 
improvement beginning from the first pulse itself. Photosensitivity started showing 
improvement after a minimum of 3 pulses. The average duration taken was around 5 
months in 85% of the patients. 
 
 Malar rash took a minimum of 2 pulses up to 5 pulses to disappear in 15% it 
still persisted at the end of 8 pulses. The average time duration taken for improvement 
of malar rash was 3.5 months. Among the cutaneous lesions, oral lesions were the first 
to show improvement. It took a minimum of 1 and a maximum of 3 pulses for 
improvement. The average duration required was 2.3 pulses in 90% of the patients. 
Discoid rash showed improvement only by 8th pulse with persistence of minimal 
scaling of discoid rash over the concha in almost all patients. Alopecia started to 
improve after the minimum of 3 pulses. The time duration noted here is the duration 
taken for the beginning of regrowth. The average number of pulses required was 5 in 
70 % of the patients. 
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 Among the systemic manifestations, fever improved in all the patients after the 
first pulse. But in 2 patients it reappeared after the 6th and 7th pulses respectively. The 
arthralgia required a minimum of two to a maximum of 6 pulses to disappear in 87% of 
the patients who had non erosive arthritis at the beginning of treatment. 
 The duration taken for clinical remission of the cutaneous and systemic 
manifestations in each patient is represented in Figure 5. 
 
ADVERSE EFFECTS: 
 The overall incidence of adverse effects was low. The commonest side effect 
noted was menstrual irregularities in 4 patients. There was oral candidiasis in 5 
patients. Pyogenic skin infections were noted in 2 patients. Urinary tract infections 
were observed in 3 patients. One patient developed acneiform eruptions after the 3rd 
pulse. There was a fall in platelet count in 2 patients, following which pulse therapy 
was withheld for 2 weeks and continued after the values normalised. None of the 
patients required platelet transfusions. There was darkening of complexion reported 
in 1 patient.   
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DURATION TAKEN FOR CLINICAL REMISSION 
 
+: Persistence of activity. 
++: Relapse of activity. 
Patient 
No 
Photosen 
-sitivity 
Malar 
rash 
Discoid 
rash 
Oral 
erosions 
Alopecia Fever Joint 
pain 
1 4 4 8+ 3 4 1 3 
2 5 3 8+ 2 - 1 4 
3 5 4 8+ 3 5 1 2 
4 6 4 8+ 2 6 1 1 
5 6 3 8+ 2 7 1 6 
6 4 4 6 - 6 1 - 
7 5 4 8+ 2 6 - - 
8 8+ 8+ 8+ 4++ 8+ 6++ 8+ 
9 3 2 6 1 4 1 6 
10 6 4 8+ 2 3 1 5 
11 8+ 8+ 8+ 6++ 8+ 7++ 7++ 
12 4 4 8+ 3 7 1 4 
13 6 5 8+ 2 3 1 5 
14 8+ 8+ 8+ - 6 1 6 
15 6 3 8+ 1 6 1 - 
16 - - 6 2 6 1 - 
17 7 4 7 1 4 1 4 
18 5 5 8+ 2 - - 7 
19 6 4 8+ 3 6 1 4 
20 6 4 6 2 3 1 3 
Figure 5 
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DURATION OF PULSE THERAPY REQUIRED: 
 
 Among the 20 patients, 7 patients (patient no.3, 7, 9, 12, 16, 17, 20) who had a 
CLASI score of 0-2 with no systemic manifestations at the end of 8 cycles were taken 
off the first phase and moved into second phase. 6 patients who had a CLASI score of 
3-10 and also had slightly elevated anti dsDNA titres were given a total of 10 pulses in 
the phase I and then moved on to phase II.  Patient no. 1 who had pulmonary disease 
and patient no.6 who still had neurological involvement and a high titre of anti dsDNA 
of 1 in 160 required an additional of 6 more pulses in phase I. Patient no.11 received 
total of 18 pulses in phase I.  
 In the eighteen patients who have completed phase I so far, the mean number 
of pulses required in phase I was 9. 
 
  Patient no.18 is still in Phase I at 11 pulses. Patient no. 8 defaulted after the 9th 
pulse. None of the patients in phase II showed relapse of disease activity so far. 
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MALAR RASH 
Before 
first pulse   After eighth pulse 
 
DISCOID RASH 
 
Before first pulse   After eighth pulse 
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SCHUSTER’S SIGN 
 
  Before first pulse   After eighth pulse 
 
ORAL EROSION 
 
    Before first pulse   After eighth pulse 
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ALOPECIA – LUPUS HAIR 
 
    Before first pulse  
 
 
 
After eighth pulse 
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RESULTS OF DEXAMETHASONE CYCLOPHOSPHAMIDE PULSE 
THERAPY IN SCLERODERMA: 
 16 patients of Systemic Sclerosis diagnosed as per the ARA criteria were given 
dexamethasone cyclophosphamide pulse therapy. All the patients were evaluated at 
the end of 12 pulses.  
 
AGE: The age distribution of patients with scleroderma included in the study varied 
from a minimum of 17 years to amaximum of 54 years. The highest number of patients 
were in the age group of 31-40 years (5 patients, 31%), followed by 25% (4 patients) 
each in the age group of 21-30 and 41-50. There were only 2 patients 12.5% above 50 
years of age and one patient less than 20 ears of age. Literature reports a peak age of 
onset between 30-50 years which is the child bearing age and declines after 
menopause.  
 
SEX DISTRIBUTION: The male to female ratio was 16:1. This is similar to the figures 
in literature which range from 5:1 to 14:1. 
 
DURATION OF ILLNESS: The duration of illness ranged from a minimum of 1 year 
to a maximum of 10 years. The average duration of illness was 3.4 years before the 
start of pulse therapy. 
 
TYPE OF DISEASE: Among the 16 patients, 62.5% (10 patients) had diffuse 
cutaneous systemic sclerosis and 37.5% (6 patients) had limited cutaneous systemic 
sclerosis. 
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RAYNAUD’S PHENOMENON:81.25% (13 patients) gave a history of Raynaud’s 
phenomenon at the beginning of pulse therapy. Following pulse therapy, no more 
episodes of Raynaud’s was reported inall the patients. The average duration taken for 
resolution averaged around 4 pulses. 
 
DIGITAL ULCERATION/SCARRING: 87.5% (14 patients) had digital pitted scars at 
the start of treatment. After 12 pulses there was absence of development of new scars 
in all (100%) patients though the scars showed only a mild improvement in 6 patients.  
 
PIGMENTARY CHANGES: Salt and pepper pigmentation ranging from minimal to 
marked was observed in all patients prior to pulse therapy. A complete disappearance 
of salt and pepper pigmentation was noted in all but one patient.   
 
FURST ET AL SKIN SCORING: 
 The distribution of the degree of skin sclerosis as measured by the Furst et al 
scoring is as follows: 
FURST SKIN SCORE BEFORE FIRST PULSE AFTER THE 12TH PULSE 
Severe (21-30) 2 1 
Moderate (11-20) 10 6 
Mild (1-10) 4  9  
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From the table it is evident that initially there were more number of patients 
with moderate degree of skin sclerosis, After 12 pulses the severity of sclerosis has 
decreased resulting in more number of patients with mild degree of sclerosis. Of the 
16 patients all but one continued to have severe sclerosis. The percentage 
improvement was 93.7%. 
 
The degree of improvement in the individual skin scores was studied using the 
paired‘t’ test,  
Where, thestandard error of difference = 0.319  
 t = 15.0816.  
The two-tailed P value is less than 0.0001 
 
  By conventional criteria, this difference is considered to be extremely 
statistically significant.    
 
 The degree of improved in the individual skin scores is represented in the 
following figure 6. 
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DYSPHAGIA: 
  At the beginning of pulse therapy 10 (62.5%) patients had dysphagia ranging 
from mild to severe degree.  There was mild to moderate degree of improvement in 
dysphagia with 12 pulses. At the end of 12 pulses, 5 patients (32.5%) continued to 
have dysphagia. The percentage improvement is 50%. In one patient with severe 
dysphagia, endoscopy guided oesophageal dilatation was done following which there 
was marked improvement in dysphagia. 
 
PULMONARY FUNCTION TESTS: 
 Of the 16 patients all 10 patients with diffuse systemic sclerosis had pulmonary 
involvement in the form of interstitial lung disease. The degree of restrictive lung 
disease was graded according to FVC levels as mild (<30), moderate (30-50) and severe 
(>50).  The distribution of pulmonary disease before and after treatment is as follows: 
 
Grade of restrictive lung 
disease 
Before first pulse 
(No of patients) 
After12th pulse 
(No of patients) 
Nil 6 11 
Mild 4 2 
Moderate 5 2 
Severe 1 0 
 
Only those who had nil disease were considered to have significantly improved. 
The percentage improvement was 60% 
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OTHERS:  
 One patient had myositis with features of proximal muscle weakness with an 
initial creatine kinase level (CPK-MB) of 2828U/L. After 6 pulses there was 
complete absence of muscle pain and the muscle power showed complete 
recovery. The creatine kinase level was normal at 192U/L.  
 2 patients had renal involvement with elevation of 24 hour urine protein, and 
mild elevation of serum creatinine. The renal functions normalised after 3 pulses in 
one patient and after 2 pulses in another. The blood pressure remained normal in 
both patients. 
There was no cardiac involvement or calcinosis cutis in any of the patients. 
 
Figure 7 
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ERYTHROCYTE SEDIMENTATION RATE (ESR): 
 ESR was elevated in 11 out of the 16 patients (68%) of the patients. At the end of 
12 pulses the ESR was within normal limits in all patients.  
ANTI NUCLEAR ANTIBODY: 
ANA was positive in 4 out of the sixteen patients at titres of 1 in 40. It was of 
speckled pattern in all four.  
ADVERSE EFFECTS: 
Minor adverse effects were noted in 7 patients. 1 patient reported weight gain and 
also had menstrual irregularities. Frequent upper respiratory tract infections were 
noted in 4 patients. Recurrent urinary tract infection was noted in 1 patient. 
Herpes zoster occurred in 1 patient. In one patient who had an initial mantoux 
positivity,pulse therapy was given under cover of ATT and no complications were 
noted.  
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DISCUSSION 
SYSTEMIC LUPUS ERYTHEMATOSUS: 
 
 Though there has been widespread use of pulse therapy for systemic lupus 
erythematosus in a number of centres especially in India, there a only a few previous 
studies which have a detailed measure of the efficacy of dexamethasone 
cyclophosphamide pulse therapy in the treatment of systemic lupus erythematosus. 
 
 The mean age of our patients was much less than the average age reported in 
literature. Also, there were a more number of female patients reported than in other 
studies. 
 
 The most common skin manifestation in our study was discoidrash (100%) 
whereas in other studies it occurred in a frequency ranging from 25-50 %. This 
discrepancy may be due to the study being conducted in the department of 
dermatology and only those patients with skin manifestations were included in the 
study.The most common manifestation in other studies was photosensitivity, which 
was the second most common (90%) in our study, along with oral erosions. Malar rash 
and hair loss was noted in 85% each were in other studies it ranged from 70-75%.  
Among the systemic manifestations arthritis was reported in 80% of our patients 
whereas in other studies it was around 57% in Indian studies to 90% reported in 
western literature. Renal involvement was seen in 35% in our study in concordance 
with other studies where it was between 21.4%-67%. 
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 The cutaneous feature to show an early response was oral erosions which 
resolved after a mean of 2.3 pulses in our study. A similar figure of 1-3 pulses 
has been reported by Dhabhaiet al5 and Pasricha et al47. The percentage 
improvement was 88% 
 Malar rash took an average of 3.5 pulses for resolution, similar to that 
observed by Dhabhai et al5 (2-5 pulses) 
 Discoid rash took a longer duration, the earliest being 6 pulses for resolution. In 
75 % of our patients it was still persistent with minimal scaling without any 
erythema at the end of 8 pulses. Previous studies also indicate that discoid rash 
was difficult to treat taking anywhere between a minimum of 2 pulses to a 
maximum of 16 pulses for complete resolution. 
  Alopecia responded after 2-7 pulses at a mean of 5 pulses. Statistics by 
Dhabhaiet al5 also report similar figures of 2-6 pulses for resolution, with the 
longest duration required being 17 pulses in one case. 
  Similar to previous study published by Dhabhaiet al5 and Sudip et al48, fever 
was the earliest to respond. In most cases it resolved with one pulse, which 
was same as the duration observed in other studies. The percentage 
improvement in our study with one pulse was 90% which is similar to that seen 
by Sudip Das et al48. 
 The number of pulses taken for remission of arthritis showed a wide variation, 
responding after the very first pulse in one patient whereas in some it took 
upto 6 pulses. The mean duration in most cases was 4.2 pulses. In the Dhabhai 
ET al5 study, the mean duration was also a similar 4 pulses. The range was from 
2-11 pulses. 
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 Of the 7 patients who showed renal involvement in our study, there was an 
initial favourable response in all of them with renal parameters and 24 hour 
urine protein normalising after 1-3 pulses. Out of these at least 3 patients 
showed exacerbation of renal disease. In the previous study, nephritis was 
reported only in fewer patients (4) with persistence of nephritis in 75% even 
after 12 pulses. 
 The seizures showed a remission after 5 pulses in this study whereas remission 
was reported after 8 pulses by Dhabhai ET al5. 
 The anti dsDNA antibodies became negative  in 35% of patients after the 8 
pulses which was similar to the figures reported by Dhabhai et al where 33% 
showed negative anti dsDNA after 8 pulses. The exact number of pulses 
required for the anti dsDNA levels to become negative in each patient could 
not be calculated in this study, since the measurements were taken at long 
intervals- i.e. at the initiation of pulse therapy, after 8 pulses and after 12th 
pulse in those who continued to have disease activity. In the previous studies 
the minimum duration to achieve a negative anti dsDNA level was 4 pulses. 
 In a nutshell, though subjective improvement was reported beginning with the 
first pulse itself, objective improvement of most of the cutaneous 
manifestations were seen commonly around the fourth pulse. The serological 
parameters improved by 8 pulses in the majority of the patients. 
 The overall adverse effect profile observed in this study was low. Common side 
effects of pyogenic skin infections and candidiasis were similar to that noted in 
previous studies. Generalised pigmentation of skin was reported in one patient 
which was also observed by Dhabhai et al and Pasricha et al4. 
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Acneiformeruptions were seen in one patient in our study which was not 
reported in the previous studies Pasrisha et al have reported generalised 
pruritus which was not seen in our study. Menstrual irregularities were seen in 
35% of our patients. Previous studies have not mentioned any reports of 
menstrual irregularities. 
 Dhabhaiet al5 have reported cardiac arrest proving fatal in one patient. No such 
adverse effects were noted in any of our patients. 
 
SYSTEMIC SCLEROSIS: 
 In our study the age of majority of the patients was between 25-45 years in 
accordance with figures reported in earlier studies. Interestingly in our study 
two patients reported after menopause at 51 and 54 years of age. 
 The female to male ratio was 16:1. This is similar to the figures in literature 
which range from 5:1 to 14:1.Indian study by Viswanathet al49 gives a similar 
figure of 13:1. 
 The skin score showed a good correlation with disease activity similar to that 
observed in previous studies. The response of skin scores to pulse therapy was 
also statistically significant. Similarly Ahmed et al6 reported moderate to 
marked improvement in skin scores with pulse therapy. 
 Viswanathet al49 reported that no new digital ulcers developed after the 
patients were started on pulse therapy although the existing scars showed 
only a mild improvement. This finding was confirmed in our study.   
 Raynaud’s phenomenon was noted in 82.5% of our patients while it was noted 
in 100% of the patients by Ahmed et al6 and Sudip et al48. This difference is 
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probably due to the warmer climatic conditions in our part of the country 
compared to the Ahmed et al6 study which was conducted in Kashmir. 
Similarly, the response of Raynaud’s phenomenon to pulse therapy was much 
higher in our study (100%) compared to the Ahmed et al study which reports a 
marked improvement in 69% of the patients 
 Dysphagia was reported in 62.5% of our patients compared to the 30% 
observed by Ahmed et al6. The response of dysphagia to pulse therapy was 
only of a moderate degree similar to that observed by Ahmed et al6. Sudipet 
al48 mention a percentage improvement of 38.5% of dysphagia. The 
percentage improvement in our study is 62.5%. In one of our patients who had 
severe dysphagia, endoscopy guided surgical dilatation had to be resorted to.  
 Pulmonary function tests showed a marked improvement in 60% of our 
patients. The improvement was observed beginning from the 3rd month with 
significant improvement after 6 pulses. Ahmed et al6 have shown improvement 
in breathlessness in 50% although they did not employ pulmonary function 
tests for assessment and only improvement of breathlessness was recorded. 
Sudipet al48 give a percentage improvement of 61.5% for breathlessness.  
 Though subjective improvement was reported by the patients at 3-4 pulses, 
objective improvement of skin sclerosis was observed only after 6-8 pulses. 
The laboratory measures of PFT showed significant  improvement in the 
majority after 6 pulses 
 The average duration of pulse therapy given was 12-18 pulses in the study 
conducted by Ahmed et al6. In our study the minimum number of pulses was 
12.  
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 In our study we noted a marked improvement in the salt and pepper 
pigmentary changes. The previous studies do not give ay detailed account of 
the response of pigmentary changes except for one case report by Pasrisha et 
al who reported complete reversal of pigmentary changes.  
 Weight gain was noted in one patient in our study. Here it was also associated 
with amenorrhoea. It was not reported in the study by Ahmed et al6. 
Tuberculous cervical lymphadenopathy was reported by Ahmed et al., but no 
such reactivation of Tuberculosis was noted in any of our patients. We noted 
increased incidence of minor upper respiratory tract infections which was also 
reported by Ahmed et al and Pasrichaet al47.  
 Studies by Davaset al50, have reported haemorrhagic cystitis in isolated cases 
when cyclophosphamide pulse was used in the treatment of lung disease in 
scleroderma. Similar complication was observed by C R Srinivaset al.52, who 
suggested that cyclophosphamide I V should be given on the second day of 
pulse along with pre and post hydration.Meticulate instructions to the patient 
in maintaining hydration and frequent voiding of the bladder prevent this 
dreaded complication. 
 Though there have been differences of opinion regarding the precipitation of 
scleroderma renal crises by high dose corticosteroids, we did not observe any 
such complication in any of our patients even in those 2 patients who had 
renal involvement. This is similar to the view observed by Pasrisha et al and 
Ramam et al22.Careful selection of patients and monitoring and appropriate 
treatment of blood pressure will help in avoiding scleroderma renal crisis 
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 Kanwar AJ et al44 reported hiccups as a specific side effect of pulse therapy. 
Interestingly none of our patients treated for SLE or Scleroderma developed 
this side effect.   
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CONCLUSION 
The following are theconclusions derived from this study 
 Dexamethasone cyclophosphamide pulse therapy is an effective therapeutic 
option for treatment of SLE and Scleroderma. 
 Rapid induction of and prolonged remission is achieved with pulse therapy. 
 Pulse therapy is safer than oral steroids with respect to decreased HPA axis 
suppression and decreased osteopenia. 
 Patient compliance is much better with pulse therapy because of the rapid 
induction of remission and relative absence of side effects. 
 Though the duration of phase I of pulse therapy is arbitrary depending upon 
the degree of remission achieved in individual patients, the mean duration 
required would be 9 pulses in SLE while in Scleroderma, a longer phase I of up 
to 12-15 months is required. 
 Unlike in bullous disorders where clinical signs of activity are clear, it is not so 
in collagen vascular disease. Hence an extended phase I and phase II should be 
given to attain remission. 
 The earlier the initiation of pulse therapy in scleroderma the better is the 
response. 
 Precipitation of scleroderma renal crisis was not observed in any of our 
patients and hence high dose corticosteroid pulse is safe in scleroderma 
provided blood pressure is maintained within normal limits by anti 
hypertensives.  
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 Scope for future improvements in pulse therapy for collagen vascular disease 
is ample with respect to clear guidelines on the duration of therapy and the 
necessity of daily cyclophosphamide 
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ANNEXURES 
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PROFORMA 
 
Name 
Age 
Sex 
Socio economic status 
Complaints 
SLE:  
 Skin lesions. 
 Oral ulcers 
 Photosensitivity 
 Arthralgia 
 Fever 
 Pleurisy 
 Seizures 
 Psychiatric symptoms 
SYSTEMIC SCLEROSIS: 
 Tightness of skin 
 Swelling of hands & feet 
 Pigmentary changes 
 Raynaud’s phenomenon 
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 Finger tip ulcers 
 Difficulty in mouth opening 
 Dysphagia 
 Abdominal pain & alteration in bowel habits 
 Tightness of chest, difficulty in breathing. 
History to rule out active infections 
History of hypertension, diabetes mellitus, ischaemic heart disease. 
Duration of illness 
Clinical features: 
 SLE:  
 Malar rash  
 Discoid rash 
 Oral ulcers 
 Alopecia 
 Joint swelling & joint line tenderness 
 Anaemia 
 Fever 
 Systemic examination of CVS, RS, GIT & CNS 
SYSTEMIC SCLEROSIS 
 Sclerosis of skin 
 Edema of hands & feet 
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 Digital ulcers& stellate scars 
 Pigmentary changes 
 Cyanosis 
 RS: Reduced chest expansion. 
 CVS 
 Per Abdomen 
Diagnosis 
Investigations 
Diagnostic tests 
 Complete haemogram 
 ANA 
 Anti – ds DNA 
VDRL 
Skin biopsy  
Tests to rule out systemic involvement: 
 Renal: Blood urea, serum creatinine, urine routine & 24 hour urinary protein. 
 Cardiac: ECG, Echocardiograph 
 Pulmonary:X ray chest, pulmonary function tests. 
 G.I: Barium swallow, OGD scopy. 
Tests to rule out latent tuberculosis: Mantoux 
Tests before every pulse: Complete haemogram, blood sugar, renal function tests, 
serum electrolytes, urine routine. 
 Tests after every pulse: serum electrolytes & urine for RBCs. 
ANA titre repeated every 4 months. 
Anti – ds DNA after 8 pulses  
89 
 
 
CONSENT FORM 
 
I ___________, give my free and full  consent  to Dr._______________ for the purpose 
of undergoing pulse intravenous injections for my illness, the nature and 
consequences of which have been explained to me. I have been completely explained 
the procedure, the need for repeated investigations, its results and possible side 
effects. I understand that more than one session may be needed for obtaining results. 
I understand the limitations of the procedure and also the final results. I have been 
provided adequate opportunity to seek information or withdraw from the study 
anytime during the study. 
_______________  
Signature of the patient/ guardian. 
 
_______________ 
Signature of doctor. 
 
________________-  
Signature of witness. 
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Pat
ien
t 
No 
Name Ag
e 
S
ex 
Dur
atio
n  
(ye
ars) 
Typ
e of 
dis
eas
e 
Skin Score Rayna
uds 
Digital 
ulcer 
/scars 
Salt and 
pepper 
pigment
ation 
PFT- Degree of 
restrictive lung disease 
G.I.T Others ESR  ADR 
B A B A B A B A B A B A  B A  
1 Manimeg
alai 
29 F 2 D 14 8 -  +  + - Mild N + - Myositis 7/14 6/14 Wt gain 
2 Sarawath
y 
54 F 3 D 17 11 +  -  +
+ 
- Mild N - - Renal 22/45 7/13 URI 
3 Thangaka
ni 
38 F 6 D 20 14 + - +  + - Moderate N ++ + - 31/45 6/12  
4 Nirmala 41 F 5 D 17 12 +  +  +
+ 
- Moderate Mild ++ +  27/52 5/11 URI 
5 Selvi 35 F 3 L 11 8 -  +  + - Normal N - - - 9/14 7/13  
6 Rahima 31 F 5 D 21 17 +  +  +
+ 
- Moderate Mild ++ + - 35/51 8/15 URI 
7 Kala 37 F 4 L 11 6 +  +  + - N N + - - 9/16 5/13  
8 Pushpava
lli 
42 F 7 D 20 15 +  +  + - Severe Moderate +++ S - 32/68 6/11 Reactivatio
n of TB 
9 Anitha 30 F 6 D 18 11 +  +  + - Moderate N + - - 24/53 7/13 URI 
10 Mala 44 F 3.5 L 9 5 -  -  + - Nil N - - - 18/34 4/11  
11 Fathima 52 F 1 D 17 10 +  +  - - Mild N + -  27/49 5/13  
12 Krishnav
eni 
27 F 2 L 8 4 +  +  - - Nil N - - - 20/45 6/13  
13 Shekar 49 M 10 D 25 21 +  +  +
+ 
+ Moderate Moderate +++ +
+ 
Renal 34/70 7/16  
14 Poongodi 17 F 2 D 14 10 +  +  + - Mild Normal + - - 22/58 6/11  
15 Lakshmi 34 F 1.5 L 8 5 +  +  - - Nil N - - - 7/13 7/11  
16 Mahesh
wari 
26 F 2 L 9 4 +  +  + - Nil N - - - 19/34 8/15 UTI 
 
SCLERODERMA MASTER CHART 
SYSTEMIC LUPUS ERYTHEMATOSUS- MASTER CHART 
 
 
B- BEFORE 1ST PULSE: A- AFTER 8TH PULSE:  +:  Persistent at 8th pulse;  ++: relapsed 
Pt.No NAME A 
G 
E 
S 
E 
X 
Durat
ion - 
mont
hs 
CLASI Photo 
sensitivity 
Malar rash Discoid rash Oral erosions Alopecia FEVER 
Before After B A D B A D B A D B A D B A D B A D 
1 Ponni 29 F 24 18 3 + - 4 - - 4 + + 8+ + - 3 + + 4 + - 1 
2 Krishnamurthi 24 M 18 29 3 + - 5 - - 3 + + 8+ + - 2 - - - + - 1 
3 Rekha 17 F 6 32 1 + - 5 + - 4 + + 8+ + - 3 + - 5 + - 1 
4 Lakshmi 19 F 2 28 2 + - 6 + - 4 + + 8+ + - 2 + - 6 + - 1 
5 Lalitha 28 F 12 31 3 + - 6 + - 3 + - 8+ + - 2 + - 7 + - 1 
6 Soundari 27 F 4 20 0 + - 4 + - 4 + - 6 - - - + - 6 + - 1 
7 Meenakshi 22 F 6 12 1 + - 5 + - 4 + + 8+ + - 2 + - 6 - - - 
8 Sandhya 17 F 12 34 20 + + 8+ + + 8+ + + 8+ + + 4++ + + 8+ + + 6++ 
9 Jenifer 34 F 4 24 0 + - 3 + - 2 + - 6 + - 1 + - 4 + - 1 
10 Thirupathamal 32 F 36 27 2 + - 6 + - 4 + + 8+ - - 2 + - 3 + - 1 
11 Gangabavani 19 F 24 27 11 + +  8+ + + 8+ + + 8+ + +
+ 
6++ + + 8+ + ++ 7++ 
12 Devaki 28 F 24 32 1 + - 4 + - 4 + + 8+ + - 3 + - 7 + - 1 
13 Rahima 32 F 18 30 2 + - 6 + - 5 + + 8+ + - 2 + - 3 + - 1 
14 Lakshmi 24 F 11 21 3 + + 8+ + + 8+ + + 8+ + - - + - 6 + - 1 
15 Selvi 26 F 18 32 3 + - 6 + - 3 + + 8+ + - 1 + - 6 + - 1 
16 Kanchana 21 F 24 19 0 - - - - - - + - 6 + - 2 - - 6 + - 1 
17 Santhanalakshmi 17 F 3 27 0 + - 7 + - 4 + - 7 + - 1 + - 4 + - 1 
18 Karthayee 23 F 12 24 2 + - 5 + - 5 + + 8+ + - 2 - - - + - - 
19 Malliga 24 F 24 32 3 + - 6 + + 4 + - 8+ + - 3 + - 6 + - 1 
20 Boopathiyamma 31 F 42 26 0 + - 6 + - 4 + - 6 + - 2 + - 3 + - 1 
SYSTEMIC LUPUS ERYTHEMATOSUS- MASTER CHART cont. 
 
Pt. 
No 
Name JOINT Renal CNS Others Anti dsDNA ANA ESR TOTAL COUUNT 
B A  B A B A B A B A Patt
ern 
B A B A B A 
1 Ponni + - 3 + - - - - Pulmn 1 : 1280 1 : 160 R 1: 1280   1: 40 55/120 35/75 4500 5100 
2 Krishnamurthi + - 4 + - - - Vasculitis - 1 : 320 1 : 40 R 1: 80        1:40 80/115 4/10 3800 4100 
3 Rekha + - 2 - - - - - - 1 : 160 1 : 10 R 1: 40 1: 40 3/18 6/14 5600 5300 
4 Lakshmi + - 1 - - - - - - 1 : 40 Negative H 1: 160 Neg 30/62 9/15 4100 4500 
5 Lalitha + - 6 - - + - - - 1 : 640 1 : 10 R 1: 160 1: 10 44/96 7/15 4800 5200 
6 Soundari - - - - - + + - - 1 : 640  1 : 160 S 1: 320 1: 10 37/80 22/41 6700 5800 
7 Meenakshi - - - - - - - - - 1 : 40 1 : 10 S 1:  40 1: 10 5/10 7/12 4500 5600 
8 Sandhya + + 8+ + + + + Pulm, 
Vasculitis 
Pulm, 
Vasculitis 
1 : 1280 1 : 1280 H 1: 1280 1: 320 65/120 28/52 4100 4200 
9 Jenifer + - 6 - - - - - - 1 : 40  Negative H 1: 40 1: 10 4/11 5/11 6700 5900 
10 Thirupathamal + - 5 - - - - Vasculitis - 1 : 40 1 : 10 R 1: 40 Neg 12/38 4/12 5400 5800 
11 Gangabavani + + 7++ + + + + - - 1 : 1280 1 : 1280 H 1: 640 1: 160 60/124 24/54 3900 4500 
12 Devaki + - 4 - - - - - - 1 : 160 Negative S 1: 80 1: 10 30/56 11/18 6100 6900 
13 Rahima + - 5 - - - - Vasculitis - 1 : 160 1 : 10 R 1: 10 1: 10 14/28 8/14 7200 6800 
14 Lakshmi - - 6 - - + - - - 1 : 320 1 : 40 H 1:160 1:10 18/44 3/14 4800 4100 
15 Selvi - - - - - - - - - 1 : 40 Negative R 1:40 Neg 12/28 7/15 6400 6700 
16 Kanchana + - - - - - - - - Negative Negative R 1:40 Neg 3/11 4/10 5600 6400 
17 Santhanalakshmi + - 4 - - - - - - 1 : 10 0 H 1: 10 1: 10 11/36 5/10 4500 5200 
18 Karthayee + - 7 + + + - Serositis - 1 : 1280 1 : 160 R 1: 320 1: 40 64/120 20/44 4600 6100 
19 Malliga + - 4 + - - - - - 1 : 640 1 : 10 H 1: 40 1: 10 24/82 5/14 4300 5100 
20 Boopathiyamma + - 3 + - - - Vasculitis - 1 : 1280 1 : 40 H 1: 40 1: 10 37/84 5/18 4600 5300 
R- Rim pattern: H- Homogenous: S- Speckled  
